# US 2008/0188000 A1 · Methods and compositions for modification of the human glucocorticoid receptor locus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188000 A1
- Document ID: US20080188000A1
- Status: Published application
- Kind: A1
- Application number: 11/983,888
- Filed: 2007-11-13
- Published: 2008-08-07
- Earliest claimed: 2006-11-13
- Assignees: Sangamo BioSciences, Inc.
- Inventors: Andreas Reik; Michael Jensen; Michael C. Holmes; Philip D. Gregory; Dale Ando
- Web page: https://patentgrep.com/patent/US20080188000A1

## CPC

- C12N 15/86: Viral vectors
- A61P 9/12: Antihypertensives
- A61P 11/06: Antiasthmatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/721: {Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/62: DNA sequences coding for fusion proteins
- G01N 33/743: {Steroid hormones}
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- G01N 2333/723: Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.

## Claims

### Claim 1

A method for inactivating glucocorticoid receptor (GR) function in a cell, the method comprising:
expressing in the cell a pair of fusion proteins, wherein each fusion protein comprises:
(i) a zinc finger DNA-binding domain that has been engineered to bind a target sequence in a GR gene, and
(ii) a cleavage half-domain;
such that the fusion proteins catalyze a double-strand break in the GR gene.

### Claim 2 (depends on 1)

The method of claim 1, further comprising introducing a polynucleotide into the cell, wherein the polynucleotide comprises a first region of homology to sequences upstream of the double-strand break and a second region of homology to sequences downstream of the double-strand break.

### Claim 3 (depends on 2)

The method of claim 2, wherein the polynucleotide further comprises exogenous sequences that are non-homologous to the GR gene.

### Claim 4 (depends on 3)

The method of claim 3, wherein the exogenous sequences comprise a transgene.

### Claim 5 (depends on 4)

The method of claim 4, wherein the transgene encodes a modified receptor.

### Claim 6 (depends on 1)

The method of claim 1, wherein inactivation of GR function prevents glucocorticoid-mediated immune suppression.

### Claim 7 (depends on 1)

The method of claim 1, wherein inactivation of GR function prevents T-cell anergy.

### Claim 8

A fusion protein comprising:
(i) a zinc finger DNA-binding domain that has been engineered to bind a target sequence in a GR gene, and
(ii) a cleavage domain or a cleavage half-domain.

### Claim 9 (depends on 8)

A polynucleotide encoding the fusion protein of claim 8.

### Claim 10 (depends on 1)

The method of claim 1, wherein the expressing step comprises contacting the cell with a viral delivery vector.

### Claim 11 (depends on 10)

The method of claim 10, wherein the vector is replication-defective.

### Claim 12 (depends on 10)

The method of claim 10, wherein the viral delivery vector is an adenovirus, a hybrid adenovirus or a non-integrating lentivirus.

### Claim 13

A method of selecting cells comprising an exogenous sequence that has been integrated into a GR gene, the method comprising
expressing a pair of fusion proteins in the cell, wherein each fusion protein comprises:
(i) a zinc finger DNA-binding domain that has been engineered to bind a target sequence in a GR gene, and
(ii) a cleavage half-domain;
such that the fusion proteins catalyze a double-strand break in the GR gene;
introducing a polynucleotide into the cell, wherein the polynucleotide comprises a first region of homology to sequences upstream of the double-strand break, a second region of homology to sequences downstream of the double-strand break and the exogenous sequence; and
treating the cells with a natural or synthetic corticosteroid under conditions such that cells not comprising the integrated exogenous sequence are killed, thereby selecting cells into which an exogenous sequence has been introduced into a GR gene.

### Claim 14 (depends on 13)

The method of claim 13, wherein the corticosteroid is synthetic.

### Claim 15 (depends on 14)

The method of claim 14, wherein the corticosteriod is dexamethasone.

### Claim 16 (depends on 13)

The method of claim 13, wherein the exogenous sequence comprises a transgene.

### Claim 17 (depends on 12)

The method of claim 12, wherein the expressing step comprises contacting the cell with a viral delivery vector.

### Claim 18 (depends on 17)

The method of claim 17, wherein the vector is replication-defective.

### Claim 19 (depends on 17)

The method of claim 17, wherein the viral delivery vector is an adenovirus, a hybrid adenovirus or a non-integrating lentivirus.
